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ABSTRACT
Despite efforts for extensive molecular characterization of cancer patients, 
such as the international cancer genome consortium (ICGC) and the cancer genome 
atlas (TCGA), the heterogeneous nature of cancer and our limited knowledge of the 
contextual function of proteins have complicated the identification of targetable 
genes. Here, we present Aberration Hub Analysis for Cancer (AbHAC) as a novel 
integrative approach to pinpoint aberration hubs, i.e. individual proteins that interact 
extensively with genes that show aberrant mutation or expression. Our analysis of the 
breast cancer data of the TCGA and the renal cancer data from the ICGC shows that 
aberration hubs are involved in relevant cancer pathways, including factors promoting 
cell cycle and DNA replication in basal-like breast tumors, and Src kinase and VEGF 
signaling in renal carcinoma. Moreover, our analysis uncovers novel functionally 
relevant and actionable targets, among which we have experimentally validated 
abnormal splicing of spleen tyrosine kinase as a key factor for cell proliferation in 
renal cancer. Thus, AbHAC provides an effective strategy to uncover novel disease 
factors that are only identifiable by examining mutational and expression data in the 
context of biological networks.
INTRODUCTION
Understanding the molecular etiology of cancer 
is challenging with various complexities including 
the multifactorial nature of the disease as well as the 
heterogeneity that exists at both genome and phenome 
levels. Advances in next-generation sequencing (NGS) 
have made it possible to profile multiple levels (e.g. 
genomic, epigenomic, and transcriptomic) of the molecular 
landscapes of patient samples at a high resolution. This 
has enabled us to identify driver abnormalities of several 
cancers, in particular those with a less heterogeneous 
molecular landscape [1–3]. However, identifying the 
aberrations that are functionally relevant from among the 
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plethora of abnormal genomic patterns, particularly given 
the presence of many passenger events, has remained 
challenging for many cancers. Integrative analysis of 
molecular data using computational methods and prior 
biological knowledge has been suggested as an effective 
approach to find cancer driver factors [4]. However, 
most bioinformatics approaches that are currently used 
to address this issue may miss important factors that 
are not affected by abnormal genetic or transcriptome 
patterns, but are nonetheless important for development 
and progression of cancer, and thus, can represent novel 
therapeutic targets.
Integrating the protein interaction network (the 
“interactome”) with genomic data has emerged as a 
promising approach to identify novel factors that are 
not captured by pathway analysis [5–8]. This approach 
is based on the “guilt by association” principle, which 
assumes shared function among interacting partners 
in protein interaction network [9]. Interpreting protein 
interactions as definitive indications of shared function 
is an association fallacy and often false [10]; however, 
these interactions provide testable hypotheses which can 
explain the underlying biology of disease. Several such 
approaches have been developed that generally follow the 
procedure proposed by Ideker et al [11] to map p-values or 
z-scores obtained from differential expression or somatic 
mutation analyses onto the interactome in order to identify 
subgraphs that are highly enriched for these aberrations 
[12, 13]. For example, HotNet finds concentrated 
subnetworks of recurrent mutations by calculating 
an influence measure between all pairs of mutated 
genes, and has been successful in exploring defective 
interaction modules in several cancer types [13]. A more 
recent approach [14] uses data of individual patients 
independently in order to define affected subnetworks, 
and to distinguish driver mutated genes from passengers.
Here, we use a novel approach, Aberration Hub 
Analysis for Cancer (AbHAC), to identify functionally-
relevant and actionable factors in cancer. AbHAC 
examines all individual proteins, including but not limited 
to hub proteins in the interaction network [15], for their 
direct connectivity with genes that are either significantly 
affected by somatic mutations or de-regulated at the 
mRNA level, and identifies “aberration hubs”, i.e. proteins 
with abnormally high interactions with genes that show 
aberrant mutation or expression. Therefore, AbHAC 
highlights candidate actionable proteins individually, and 
is capable of identifying factors that are not affected by 
genome or transcriptome aberrations themselves but are 
important players in cancer according to the significantly 
high number of deregulated proteins interacting with them.
We use several lines of evidence to show that 
these aberration hubs represent important cancer-related 
factors. First, we show that aberration hubs can distinguish 
different cancers and can identify relevant proteins in 
different subtypes of breast cancer using data from The 
Cancer Genome Atlas (TCGA) [16]. Next, we apply 
AbHAC to the International Cancer Genome Consortium 
(ICGC) Cancer Genomics of the Kidney (CAGEKID) 
data [17] for the clear cell subtype of renal cell carcinoma 
(ccRCC). We show that AbHAC can identify known 
activated molecular networks such as VEGF and Src 
pathways, but additionally uncovers new candidate 
factors. These include spleen tyrosine kinase (SYK), 
which we further validate as a key proliferation regulatory 
factor in renal cancer cells.
RESULTS
Implementation of AbHAC
The concept of AbHAC is to identify proteins whose 
local neighborhoods, constituted by their direct interacting 
partners, are significantly enriched for aberrant proteins 
(e.g. those encoded by mutated genes or translated from 
aberrantly expressed transcripts). AbHAC is based on 
the hypothesis that proteins with a significantly high 
number of deregulated interacting partners are likely 
important hubs that contribute to cancer. To implement 
AbHAC, we first constructed a whole human protein 
interaction network using the PSICQUIC [18] query 
system (see Methods). After excluding proteins that do 
not have experimentally verified annotated interactions, 
the interaction network included a total of 11,851 
proteins with an average of 10 interactions per protein 
(median of 3). Then, for a particular cancer dataset, we 
calculated for each protein in the network the number of 
its direct interacting partners with and without abnormal 
genetic patterns (e.g. the number of interacting partners 
with genes identified as being significantly mutated) or 
abnormal expression patterns (differential expression 
between tumor and normal samples). As we are interested 
in the subset of proteins that have more abnormal partners 
than expected by chance, we calculated a p-value for 
each protein for the observed numbers of normal and 
abnormal partners using a one-sided Fisher’s exact test 
(Figure 1). To correct for multiple testing, considering the 
complex dependencies in the protein interaction network 
and the resulting correlations among the p-values, we 
randomized the protein interaction network by permuting 
proteins that have similar number of interaction partners 
(see Methods and Supplementary Figure 1). Enrichment 
of various molecular aberrations can be examined by 
adjusting the inclusion criteria for deregulated partners. 
For example, we can focus uniquely on proteins whose 
direct interacting neighborhoods are enriched in genes 
deregulated at either RNA level (up- or down-regulated 
genes) or DNA level (significantly mutated genes), 
or we can undertake an integrated analysis to look for 
enrichment of aberrations in both RNA and DNA. Table 1 
presents further examples of different aberration category 
queries.
Oncotarget25168www.oncotarget.com
Figure 1: AbHAC algorithm. For all the proteins in the interaction network, we assess if their local neighborhood is enriched for 
proteins whose coding genes are significantly mutated or/and aberrantly expressed (see Table 1 for different aberration categories). We 
consider each protein as an independent hypothesis, and use Fisher's exact test to evaluate over-representation of aberrant molecules among 
interacting partners of a given protein. We generate 100 permuted networks to correct for multiple testing.
Aberration hubs are characteristics of tumor 
types
To test whether the aberration hubs are associated 
with clinical or phenotypic variations, we applied AbHAC 
to TCGA breast cancer [16] and the ICGC clear cell renal 
cell carcinomas (ccRCC) [17] datasets (Supplementary 
Tables 1-8), and investigated the distribution of aberration 
hubs across these samples. We calculated AbHAC p-values 
for all proteins in patients with breast or renal cancer (see 
Methods for details), and performed principal component 
analysis (PCA) using these p-values. This analysis showed 
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that “aberration hubs” are different between breast cancer 
and ccRCC, and can be used to clearly separate patients 
with different cancers (Figure 2a). To confirm that this 
observation was not due to differences in the tissue of 
origin (kidney vs. breast) and rather represent cancer-
associated effects, we further examined clustering of 
breast cancer samples using AbHAC p-values by PCA. 
This analysis revealed that the first three principal 
components differentiating between breast cancers are 
significantly associated with known PAM50 subtypes 
of breast cancer (ANOVA p < 10-5), confirming that 
the main diversity in AbHAC p-values is related to the 
subtype-specific differences (Figure 2b). Following this 
observation, we used a support vector classifier trained 
on half of the samples to predict the PAM50 subtype of 
remaining samples. This classifier achieved very high 
specificity and sensitivity in one-versus-all classification 
(see Methods and Figure 2c). Therefore, these results 
showed that cancer aberration hubs are not random and 
can provide clinical and biologically-relevant information.
Aberration hubs in breast cancer
Breast cancer is a heterogeneous disorder with 
different subtypes, each characterized by distinct 
molecular alterations and clinical behavior [19]. The 
TCGA datasets provide comprehensive molecular 
landscapes of intrinsic subtypes as defined by PAM50 
classifier [20]. Using these datasets (Supplementary Tables 
1-6), we applied our statistical approach to the data from 
the PAM50 subtypes of breast cancer to identify proteins 
that might be relevant for each subtype (see Methods for 
details). Our analysis identified 74 aberration hubs using 
different aberration categories in different PAM50 classes 
(False discovery rate (FDR) < 0.05; Supplementary Table 
9). To verify if any of the 74 proteins had previously been 
associated with breast cancer, we conducted a literature 
review using MeSHOP [21] with “Breast Neoplasms” 
as the MeSH term to count how often the proteins are 
reported to be implicated in breast cancer. We found a total 
of 1294 reported proteins of which 39 were in our list. This 
represents 4.7-fold enrichment of breast cancer-associated 
proteins among the identified aberration hubs compared to 
the background of other proteins in the interaction network 
(p = 6.9 × 10-11, Fisher's exact test; Supplementary Table 
9), supporting the efficacy of AbHAC to identify relevant 
molecules in a given cancer dataset.
We further questioned if genes encoding any of 
these aberration hubs are among significantly mutated or 
abnormally expressed genes in breast cancer according 
to TCGA datasets. We observed that only one of these 
74 molecules (CDKN1B) is significantly mutated in 
breast cancers, and that 50 of them are not differentially 
expressed at mRNA level in tumors (all together or at 
subtype-level) when compared to non-tumor control 
samples (Supplementary Table 9). In addition, only 15 of 
the 39 aberration hubs, which were connected to breast 
cancer based on previous literature, have significant 
differential expression at mRNA level or a mutation. This 
further illustrates that AbHAC is capable of identifying 
relevant factors that cannot be identified directly by 
interrogating mutational or expression patterns of genes.
Our further analysis showed that 53 of the 74 
breast cancer aberration hubs are specific to one of the 
PAM50 subtypes in a given aberration category (Table 
2, Supplementary Table 9 and Supplementary Figure 
2). Pathway analysis of these proteins, using KEGG 
datasets, revealed that aberration hubs found in luminal 
breast tumors are enriched in PI3K-Akt pathway and 
FOXA1 regulatory network (Supplementary Table 10), 
in line with a high prevalence of PIK3CA and FOXA1 
mutations in this subtype [22, 23]. In addition, hubs of 
basal-like subtype are enriched in DNA replication and 
cell cycle pathways (FDR < 8.75 × 10-5), which confirms 
previous reports on importance of these pathways in 
basal-like tumors [24]. Specifically, we observed several 
components of “origin recognition complex” (ORC) 
including ORC1, 2, 3, 5 and 6, and “mini-chromosome 
maintenance” (MCM) such as MCM3, 6 and 7, 
which are important factors for initiation of genome 
Table 1: Definition of the aberration categories
Aberration 
category Interacting partners are enriched in
Proteins enter the analysis if they have 
following interacting partners
UP Upregulated genes At least one upregulated
DOWN Downregulated genes At least one downregulated
MUT Mutated genes At least one mutated
MUT.UP Upregulated or mutated genes At least one mutated and one upregulated
MUT.DOWN Downregulated or mutated genes At least one mutated and one downregulated
DE Upregulated or downregulated genes At least one differentially expressed
MUT.DE Differentially expressed or mutated genes At least one mutated and one differentially expressed
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replication, among aberration hubs of basal-like tumors 
(Supplementary Table 10).
Among the 74 aberration hubs we identified in 
TCGA breast cancer datasets, 45 were not affected by 
somatic mutations or significant changes at mRNA 
levels in any of the PAM50 subtypes. We hypothesized 
that at least some of these factors may be deregulated at 
translational or post-translational levels. Therefore, we 
investigated the status of these aberration hubs at protein 
level using the TCGA proteome and phosphoproteome 
data for breast cancer [25]. We used t-test to compare 
normalized expression level of each peptide or 
phosphopeptide in one PAM50 subtype against other 
PAM50 subtypes. We observed that 5 out of these 45 
aberration hubs exhibit differential expression patterns at 
protein level (for specific phosphopeptides) in the same 
breast cancer subtype in which they had been identified 
by AbHAC as compared to tumors of other subtypes 
(Supplementary Table 11). These include ZNF652, 
XRCC5, EIF6, and HIST1H4A in basal-like, and CDC5L 
in luminal B tumors. These findings show that AbHAC 
is able to identify molecules that may specifically be 
implicated in a particular subtype of cancer and suggest 
that novel molecules identified through AbHAC approach 
may be functionally relevant in particular intrinsic 
subtypes of breast cancer.
Aberration hubs in renal cancer
We applied the same analysis to ccRCC using 
information about somatic non-silent mutations and 
abnormal gene expression patterns that have been 
recently identified through the CAGEKID program [17] 
(Supplementary Tables 7-8; see Methods for details). 
AbHAC analysis of these datasets identified 47 aberration 
hubs in renal tumors (FDR < 0.05; Supplementary Table 
12). We noticed that, although identified independently, 
several of these aberration hubs were connected together 
through protein-protein interactions and formed a protein 
network that included several known cancer driver factors 
such as MYC, EGFR, PIK3C2B, CDK1, and KDR 
(Supplementary Figure 3). Further analysis of this network 
revealed 25 inter-connected aberration hubs that were 
enriched in up-regulated genes among their interacting 
partners. (Figure 3a, Table 3). This core was composed of 
several proteins with angiogenic functions in renal cancer 
including VEGFA, NRP1 and KDR (VEGF receptor-2), 
the latter of which may have predictive value in ccRCC 
[26]. Src kinase signaling members were also predominant 
in the core, including SRC, LCK, LYN, FYN and PTPN6, 
among which LYN has been causally implicated in renal 
cancer [27, 28]. In addition to interacting extensively with 
deregulated genes, the mRNA of many of these molecules 
Figure 2: Aberration hubs distinguish between different tumor types and subtypes. (a) Principal component analysis on 
AbHAC p-value matrices of TCGA breast cancer samples and ICGC renal cell carcinomas differentiates them based on tumor tissue of 
origin. First two principal components of AbHAC p-values for proteins enriched with differentially expressed (DE), downregulated (Down) 
or upregulated (UP) genes (in tumors relative to normal) among their direct interacting partners are shown. (b) Principal component 
analysis on AbHAC p-value matrices of TCGA breast cancers. For each patient, differentially expressed genes are identified as the 5 percent 
highest and lowest values when normalized to average values of non-tumor samples. These genes are then used for AbHAC analysis. 
P-values are calculated by ANOVA test. First three principal components differ among PAM50 subtypes of breast cancer. (c) The support 
vector machine classifier was trained on half of the breast tumors by grid search and 4-fold cross validation. The parameters identified by 
this approach were then applied on the other half of the breast tumors to predict their subtypes. The area under the curve (AUC) analyses 
show high sensitivity and specificity of AbHAC to predict subtype of breast cancer.
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is over-expressed in tumors as compared to normal 
renal tissue. This is in line with the oncogenic activities 
reported for them (Table 3). Notably, some proteins 
included in this core had not been directly reported in 
renal cancer (proteins without a PMID in Table 3). Among 
these potentially new relevant proteins, spleen tyrosine 
kinase (SYK) was particularly attractive, because it is a 
tyrosine protein kinase which has not been identified as 
being differentially expressed at mRNA level between 
tumor and control samples whereas it was identified as 
an aberration hub in four aberration categories (Table 
3). We re-examined the RNA-Seq data of ccRCC and 
control samples for SYK transcripts, and found that while 
SYK was not differentially expressed, it was alternatively 
spliced in tumors as compared to non-tumor samples in 
24 out of 44 (54.5%) studied patients. This was due to an 
aberrant splicing pattern introducing a new exon to SYK 
transcripts resulting in a longer isoform of the protein in 
tumor samples (SYK-L with 635 amino acids coded by 
transcripts ENST00000375754 and ENST00000375746) 
compared to a shorter isoform (SYK-S with 612 amino 
acids coded by transcripts ENST00000375751 and 
ENST00000375747) (Figure 3c and Supplementary 
Figure 4). We observed that the longer isoform of SYK 
was significantly more abundant in tumors as compared to 
normal samples (p < 0.008, Figure 3b and Supplementary 
Figure 4). We further assessed the relative abundance of 
the two SYK isoforms by immunoblotting in matched 
tumor and normal samples from four additional patients. 
This analysis revealed that while both isoforms were 
present in normal tissue specimens, only the long isoform 
was detected in tumors (Figure 3d). Interestingly, a similar 
pattern has recently been reported in ovarian cancer, 
where abnormal splicing of SYK supports cancer cell 
proliferation and survival [29]. Therefore, we used RNAi 
to examine whether modulation of long isoform of SYK 
influences the proliferation of renal cancer cells. Silencing 
of the SYK long isoform by two independent specific 
siRNAs substantially reduced proliferation of renal 
cancer cells in 786-O and A498 cell lines as measured 
by colony-formation and viability assays (Figure 4a-4e). 
Furthermore, suppression of SYK long isoform induced 
activation of apoptosis as examined by caspase assay and 
flow cytometry analysis (Figure 4f-4g). These findings 
showed that long isoform of SYK plays an important 
role in the proliferation and survival of renal cancer cells, 
highlighting the power of the AbHAC approach to identify 
functionally relevant factors in cancer datasets.
DISCUSSION
In the present study, we undertook a novel 
integrative approach to identify proteins whose 
interacting partners are significantly affected by abnormal 
molecular patterns. This was based on our hypothesis 
that enrichment of molecular aberrations in the local 
interacting neighborhood of proteins can be associated 
with phenotypic variations (similar to that observed 
for deregulation at gene expression level [30, 31]), and 
can therefore help identify factors that are relevant to a 
specific phenotype (e.g. cancer or a specific subtype of 
cancer). Two possible scenarios can explain function of 
a direct interaction between two proteins: (i) one protein 
modulates activity of the other protein (where direction 
of edges matters); (ii) both proteins form a complex to 
assert a function (un-directional interaction)[32]. Since 
our hypothesis does not prefer any of the abovementioned 
scenarios over the other, we assumed all protein 
interactions are undirected. This assumption helped 
expanding our analysis to include interactions for which 
the directionality is not known. We further validated the 
relevance of the identified factors by literature review and 
by functional experiments.
Table 2: Aberration hubs identified specific to a PAM50 subtype of breast cancer in a given aberration category by 
AbHAC (FDR < 0.05)
PAM50 subtype Molecules with supporting literature in the same PAM50 subtype Potentially novel relevant factors
Basal-Like CDC45, MCM7, AURKA, PCNA, 
CHEK1, TFDP1
HIST1H4A, MCM3, MCM6, MCMBP, ORC6, 
CDC6, XRCC6, ORC2, ORC1, ORC5, WRN, NEK6, 
MAD2L1BP, EIF6, XRCC5, OSM, ZNF652, MYBPC2, 
AIRE, CHD1L, HDGF, SNW1
HER2-enriched CXCR3, RACGAP1 ORC3, TONSL, COL1A2, CEACAM6, CCR3, KRT32, 
SEZ6L2, DPP8
Luminal A HSPB8 OSM, COL5A1, PDE4DIP, EGFR, ECM1, COL5A2
Luminal B ANAPC4, OPRK1, GOPC, CDC27, CDKN1B, 
S100A9, BRCA1, STK4, CDK3
List of all aberration hubs identified in breast cancer, their associated aberration categories, and references to the literature 
are presented in Supplementary Table 9.
Oncotarget25172www.oncotarget.com
Unlike other approaches to protein network 
analysis, AbHAC analyzes the neighborhood of a given 
protein as a distinct variable independent from the 
rest of the interactome, and regardless of mutational or 
transcriptional patterns of its gene. This feature allows 
pinpointing “individual” proteins rather than interaction 
modules that may be involved in a disease. Furthermore, 
this feature gives AbHAC the ability to identify factors 
that may not be mutated or differentially expressed, but 
may be functionally relevant in cancer through other 
mechanisms. As a proof of principle, we demonstrated the 
functionality of this approach by showing that enrichment 
of abnormally expressed or mutated genes in interacting 
neighborhoods of proteins can classify tumors based 
on their pathological differences (comparison between 
breast and renal cancers, and between PAM50 subtypes 
of breast cancer). To identify proteins whose interacting 
neighborhoods are deregulated in a certain group of 
tumors, we performed Fisher’s exact test and corrected 
for multiple testing by randomizing protein interaction 
networks through permuting proteins that have similar 
numbers of interacting partners. This permutation step 
provides a statistical confidence for the data generated by 
AbHAC by accounting for complex dependencies of any 
input dataset, and thereby distinguishes our method from 
the existing ones. For example, the DIAMOnD algorithm 
[33] follows a similar procedure to connect known disease 
genes in the protein interaction network by identifying 
disease modules; however, it lacks a statistical component 
to assign the level of significance for each observation, and 
to measure the false discovery rate associated with each 
analysis. We analyzed the same interactome and genesets 
(aberrantly expressed or mutated) with both AbHAC and 
DIAMOnD. For AbHAC we used FDR < 0.05 to identify 
Figure 3: SYK, an aberration hub in ccRCC, is not affected by differential gene expression but by abnormal splicing. 
(a) A core of inter-connected aberration hubs that are enriched with up-regulated genes in their interacting neighborhood in renal cancers are 
shown. Each gray line indicates a direct interaction. Red and black colors highlight aberration hubs that are upregulated or not differentially 
expressed at mRNA level in tumors as compared to normal samples, respectively. PI3KR1, represented by a blue circle, is the only mutated 
aberration hub. All aberration hubs identified in ccRCC by AbHAC are shown in Supplementary Figure 3. (b) SYK is an aberration hub 
that was not differentially expressed at the mRNA level. Further investigation revealed an abnormal splicing pattern between normal 
and tumor samples involving four SYK transcripts (ENST00000375751: SYK-S1; ENST00000375747: SYK-S2; ENST00000375754: 
SYK-L1; ENST00000375746: STK-L2) (see details in Supplementary Figure 4). P-values were calculated using Mann-Whitney U test. 
(c) As an example, the status of SYK spliced variants is shown for patient L405 by sashimi plot. The predominance of SYK-L2, coding for 
the long isoform, in tumor (denoted by blue color) compared to normal renal tissue (shown in red color) is shown. (d) Western blot analysis 
of additional sample pairs showing that the longer isoform of SYK is abundant in RCC samples (T) as compared to patient-matched normal 
kidney tissue (N).
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aberration hubs, and for DIAMOnD we chose the first 
100 top hits, which is larger than the maximum number 
of significant aberration hubs identified by AbHAC in any 
of our analyses. While the number of targets identified 
by DIAMOnD was always larger than that identified by 
AbHAC, there were several cases of targets only identified 
by AbHAC and not by DIAMOnD in this controlled 
comparison. For example, 29 out of 65 AbHAC targets 
(in 3 aberration categories of UP, DOWN or DE) were 
unique to AbHAC in the specific comparison of breast 
Table 3: Interconnected aberration hubs that were enriched with up-regulated genes among their interacting 
partners in ccRCC (FDR < 0.05)
Uniprot HGNC Aberration Category*
Examples for 
supporting literature 
(PMID)
Status of gene 
expression 
(Tumor/Normal)
Molecules with 
supporting 
literature
P22681 CBL UP & MUT.UP 21949687 NA
P07766 CD3E DE & UP & MUT.UP 9796963 Up-regulated
P48023 FASLG DE & UP & MUT.UP 
& MUT.DE
10353760 Up-regulated
P06241 FYN UP & MUT.UP 22814579 NA
P62993 GRB2 MUT.UP PMC2737331 NA
P05556 ITGB1 UP 23499501 NA
P35968 KDR DE & UP & MUT.UP 24786599 Up-regulated
P06239 LCK DE & UP & MUT.UP 9796963 Up-regulated
P07948 LYN DE & UP & MUT.UP 22814579 Up-regulated
O14786 NRP1 UP 18974107 Up-regulated
P27986 PIK3R1 MUT.UP PMC4355729 NA
P12931 SRC UP & MUT.UP 22814579 NA
Q13509 TUBB3 UP 25527909 NA
P15692 VEGFA UP & MUT.UP 15793222 Up-regulated
Potentially novel 
relevant factors
Q13444 ADAM15 UP & MUT.UP NA NA
P20963 CD247 UP NA Up-regulated
P46108 CRK MUT.UP & MUT.DE NA NA
P17813 ENG UP NA Up-regulated
P16333 NCK1 MUT.UP NA Up-regulated
P19174 PLCG1 MUT.UP & MUT.DE NA NA
Q9Y2R2 PTPN22 UP NA Up-regulated
P29350 PTPN6 DE & UP & MUT.UP 
& MUT.DE
NA Up-regulated
O60880 SH2D1A UP NA Up-regulated
P43405 SYK DE & UP & MUT.UP 
& MUT.DE
NA NA
P42768 WAS DE & UP & MUT.UP NA Up-regulated
*In the aberration categories, “&” refers to independent aberration categories, and “.” symbol denotes an integrative analysis 
including two classes of aberrations. See Table 1 for the definitions of the aberration categories.
Examples of supporting literature and status of mRNA expression are shown for each aberration hub. Definition of each 
aberration category is provided in Table 1.
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Figure 4: Inhibition of long isoform of SYK impairs proliferation of renal cancer cells. Silencing of SYK long isoform 
through RNAi (siSYK-L1 and siSYK-L2) in renal cancer cell lines 786-O and A498 was confirmed by western blot (a) and qRT-PCR 
(b) analyses. (c) SYK-L knockdown reduces the colony-forming ability of 786-O and A498 cells as compared to the negative control 
(siControl) (n=3). (d) Representative images of colony formation assays are shown. Cell viability (e) and Caspase 3/7 activity (f) after 
knockdown of long isoform of SYK. Values are normalized to si-Control (non-targeting siRNA). (g) Changes in cell cycle distribution 
upon knockdown of long isoform of SYK in A498 cells. Whereas both SYK isoforms are detected in 786-O cells, the long isoform is 
predominantly detected in A498 cells and suppressed by RNAi supporting the functional relevance of this isoform.
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cancer subtypes, and 12 of these hubs had a breast cancer 
literature according to MeSHOP. Similarly, for renal 
carcinoma, 26 out of the 39 targets identified by AbHAC 
(in 3 aberration categories) were not among the list of 
DIAMOnD results (Supplementary Figure 5). VEGFA, 
KDR, LYN, CD3E and LOX are among those factors 
that are not identified by DIAMOnD but have a renal cell 
carcinoma associated literature support (Supplementary 
Table 13).
The correction for multiple testing provided a 
high confidence for the data generated by AbHAC. For 
example, only four proteins (INCENP, MIS12, CDK1, 
COL5A1) were common in the list of aberration hubs 
identified through the same analysis applied to breast 
cancer (with total of 74 aberration hubs) and renal 
carcinoma datasets (with total of 47 proteins aberration 
hubs), indicating that AbHAC is capable of finding 
proteins that are specifically deregulated in a given cancer. 
The above molecules identified in both breast and renal 
cancers have already been implicated in multiple cancers 
based on previous literature. For example, CDK1 is 
shown to be an inhibitor of FOXO1, which is known as 
a common tumor suppressor in different types of human 
cancer [34]. Accordingly, the additional factors identified 
in this study may present novel relevant players in breast 
cancer. Our results showed that several proteins with key 
roles in the initiation of genome replication are significant 
aberration hubs of basal-like tumors, shedding light on 
the underlying molecular mechanisms of this aggressive 
tumor entity. Importantly, the careful selection of genes 
as input for AbHAC analysis assists in the identification 
of functional-relevant aberration hubs. Applying analytical 
methods such as MuSiC [35] or MutSigCV [36], which 
identify significantly mutated genes, to cancer sequencing 
data is an appropriate approach to exclude genes affected 
with passenger alterations from the input list for AbHAC 
analysis.
To assess the reproducibility of AbHAC results, we 
applied this method to an additional independent genomic 
datasets of renal (TCGA) cancer and compared the results 
to our preceding findings in CAGEKID datasets. This 
analysis showed a strong correlation (Pearson R > 0.7, p < 
10-16) between results of AbHAC analysis of these datasets 
(Supplementary Figure 6), suggesting that AbHAC results 
are not database-specific.
Furthermore, we systematically assessed the 
extent of possible dependency between the deregulated 
neighborhood of an aberration hub and deregulation 
of the hub itself. We compared the AbHAC p-value of 
proteins and the differential gene expression level of their 
corresponding genes in the above-mentioned datasets. We 
did not observe a significant correlation between AbHAC 
p-value and the extent of deregulation at mRNA level 
for a given molecule (Supplementary Figure 7). Overall, 
the AbHAC p-values are not significantly influenced by 
expression levels of the corresponding genes. In other 
words, aberration hubs are not necessarily affected 
by extreme abnormal gene expression themselves. 
These findings suggest that the analysis of deregulated 
neighborhoods among interacting partners of proteins can 
lead to the identification of factors that are not captured 
by the analysis of mRNA expression levels alone, and 
may therefore uncover new relevant molecules and 
pathways. This is exemplified by the identification of 
SYK in renal cancer; while AbHAC predicted SYK as 
a novel relevant factor, SYK had not been identified 
as an up-regulated gene in ccRCCs. Although we had 
previously identified it as being affected by abnormal 
splicing patterns in ccRCC [17], it was not among the 
top-ranked genes. Nevertheless, AbHAC highlighted 
SYK as a strong aberration hub based on the enrichment 
of abnormal genomic patterns in its direct interacting 
neighborhood. This example highlights the efficacy of 
AbHAC to identify factors that are functionally relevant 
in the large list of genes affected by abnormal molecular 
patterns in tumors. Furthermore, our findings revealed an 
oncogenic core signaling which is activated in tumors. 
Molecules involved in this network are members of 
VEGF signaling, the main driver of angiogenesis, which 
is a known target for the development of therapies 
against ccRCC. Resistance to anti-VEGF agents, 
however, often develops in patients with metastatic RCC, 
limiting treatment efficacy [37]. Our findings uncover 
novel affected factors interacting with members of this 
signaling pathway, which may serve as alternative targets 
for future drug development strategies. Interestingly, SYK 
has been reported as an activator of the VEGF pathway 
by phosphorylating VEGFR-2 receptor [38], which was 
also in the network that we identified in the current study. 
Furthermore, several members of the Src kinase family 
were present in this network. According to the close 
cross-talk between VEGF receptor and Src signaling 
[39], inhibition of aberrantly regulated proteins of the 
Src pathway may provide an additional route to control 
of tumor angiogenesis. Notably, Src signaling is also 
involved in the regulation of PI3K-Akt-mTOR pathway, 
which has been recognized as a relevant therapeutic target 
for ccRCC [40].
Collectively, our results from analyzing two 
cancer datasets highlighted proteins whose relevance to 
the studied cancers is supported by previous literature, 
and provided a list of potentially novel relevant factors 
for further investigation in future studies. Similarly, 
AbHAC can be applied to analyze molecular aberrations 
of other cancers, and other diseases in general. Likewise, 
the method can be used to study proteome profiles or 
combinations of different layers of genome and proteome 
information as well. As such, AbHAC and similar methods 
can support a systems level understanding of cancer and 
other complex disorders.
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MATERIALS AND METHODS
Software packages
CRAN project R software [41] has been used 
for most of the analysis presented here. Some of the 
analysis and figures have used the following CRAN and 
Bioconductor packages; ggplot2 [42], limma [43], edgeR 
[44], PSICQUIC [18] and Uniprot.ws [45]. Figures of 
interaction networks were generated using cytoscape [46].
Protein interaction network
Using PSICQUIC [18] and UniProt.ws Bioconductor 
packages, we acquired the protein interaction network of 
all the Uniprot accessions from the following databases for 
Homo sapiens: DIP, InnateDB, IntAct, MatrixDB, MINT, 
I2D-IMEx, InnateDB-IMEx, MolCon and BindingDB. We 
filtered out interactions that had been reported only based 
on colocalization experiments. This left us with 11,851 
proteins in total that have an average of 10 interaction 
partners (median of 3). All duplicated interaction partners 
were removed in this undirected protein interaction 
network.
Datasets
For the breast cancer analysis, we used the publicly 
available TCGA breast cancer datasets of somatic 
mutations and microarray expression profiles for 497 
patients grouped into the 4 major PAM50 subgroups 
(basal-like, HER2-enriched, luminal A and luminal B)[20]. 
We did not include the normal-like subtype because of its 
significantly lower number of samples compared to other 
subtypes. Original PAM50 class of these patients was 
adopted from Supplementary Table 1 of the TCGA paper 
[16]. We only included mutational data for the 54 genes 
reported as being significantly mutated in supplementary 
information of the TCGA paper [22] in our analysis 
(Supplementary Table 1).
For the renal cancer analysis we used CAGEKID 
datasets [17] generated from genome-sequencing 
of 94 patients and RNA-Seq of 61 tumors (45 with 
matched normal kidney tissue control samples). Somatic 
mutations were included which affected 583 genes that 
were either recurrently mutated in ccRCCs or were 
identified as significantly mutated genes as reported in 
Supplementary data 5 of the original CAGEKID study 
[17] (Supplementary Table 7).
Differential gene expression analysis
For mRNA differential expression analysis, we 
first converted gene symbol IDs to Uniprot accession 
IDs and only kept those that had any level of information 
in the interactome. To identify differentially expressed 
genes between groups of samples (all tumors or a class 
of tumors compared to non-tumor samples) we used 
limma [47] package with TREAT [48] for differential 
expression analysis of TCGA breast cancer normalized 
Agilent microarray data (level 3). The lfc parameter was 
set to 1, with Benjamini Hochberg (BH) FDR [49] cutoff 
of 0.05 in order to identify genes that are significantly 
differentially expressed in tumors with a minimum of 
2-fold change difference compared to 22 nontumor breast 
tissue samples (Supplementary Table 2). This procedure 
was also performed for each PAM50 group of patients 
(except Normal-Like tumors as discussed above in the 
Datasets) independently (Supplementary Tables 3-6). To 
define genes differentially expressed in a given patient, 
we calculated a log2FC by dividing the expression of each 
gene in the patient’s tumor by the average of expression 
values for that gene across nontumor control samples. 
For each patient, we considered the top 5% of genes for 
each direction (down or up) as differentially expressed. 
Differential gene expression of renal cancer samples was 
performed using edgeR Bioconductor package using the 
classic edgeR design for comparing selected tumors to 
all nontumor tissues. We used Benjamini and Hochberg 
method of multiple testing correction with a 5% cutoff 
of FDR. We also filtered out genes with absolute log2FC 
values below 1 (genes with differential fold-changes 
below 2) (Supplementary Table 8).
Identification of aberration hubs
We used one-tail Fisher’s exact test as a statistical 
approach to evaluate enrichment of genomic or 
transcriptomic aberrations at the level of each subnetwork. 
Fisher’s exact test was used to calculate probability of 
significance for the number of deregulated interacting 
partners of a protein by taking into account the total 
size as well as number of all deregulated proteins in the 
interactome. In this setup, we calculated p-values against 
the null hypothesis that interacting neighborhood of 
each protein shows a random enrichment in deregulated 
molecules. To correct for multiple testing, we used a 
permutation approach as discussed below. The reason for 
this is that the complex structure of the protein interaction 
network would create dependencies among the p-values.
Multiple testing correction
In AbHAC, we performed Fisher’s exact test on 
local neighborhood of each protein independently while 
complex interactions exist among the proteins. To estimate 
a false discovery rate based on the p-values, for 100 times 
we generate permuted networks and calculate the p-value 
for all of the proteins at each iteration. For this purpose, 
we swapped the label of the proteins that have similar 
number of interacting partners. Proteins with degrees 
>60 were placed in four equal size groups, with other 
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groups consisting of proteins with exact same degrees, 
and labels were randomly swapped within each group. 
We defined the FDR as the median number of proteins 
passing significance threshold in the 100 permuted 
networks divided by the number of proteins passing the 
same significance threshold in the actual network. We then 
found the p-value cutoff corresponding to FDR of 5% by 
iterating through sorted p-values.
Proteome and phosphoproteome data analysis
We obtained information about protein and 
phosphopeptide assembly and their relative abundance 
for TCGA breast cancer samples from clinical proteomic 
tumor analysis consortium (CPTAC; https://cptac-
data-portal.georgetown.edu/cptac/s/S015). For each 
aberration hub, we examined if the protein or any of its 
phosphopeptides had a significantly different level in 
comparison of one subtype against other subtypes (t-test 
p-value < 0.05 & |fold change| > 0.5).
Pathway analysis
We used ConsensusPathDB [50] for pathway 
enrichment analysis and used the significance cutoff of 
0.05 for multiple test corrected p-values. Results of KEGG 
and PID from this software are provided as figures and 
tables in the manuscript.
Cell culture
The established renal cancer cell lines A498 and 
786-O were purchased from American Type Culture 
Collection (ATCC) (Rockville, MD, USA). The cell lines 
were cultured according to the recommendations of ATCC 
in the appropriate cell culture media and were incubated at 
37°C in a humidified incubator with 5% CO2.
siRNA transfection
The siRNA-mediated knockdown (KD) of SYK 
was carried out in 786-O and A498 cells. Briefly, two 
Silencer Pre-designed siRNA against SYK long isoform 
[29] with following sequences were used: SYK-L1 siRNA 
sequence: 5’-GUUCCCAUCCUGCGACUUGTT-3’ 
(sense); 5’-CAAGUCGCAGGAUGGGAACTT-3’ 
(antisense) and SYK-L2 siRNA sequence: 
5’-GGUCAGCGGGUGGAAUAAUTT-3’ (sense); 
5’-AUUAUUCCACCCGCUGACCTT-3’ (antisense). 
Silencer Negative Control siRNA (Ambion) was used 
as a control. Cancer cells were reverse transfected 
with siRNAs (final concentration of 35 nM) using 
Lipofectamine RNAiMAX Transfection Reagent 
(Invitrogen Corporation) according to the manufacturer's 
instructions.
Western blot analysis
Protein extraction and western blotting from 
cell lines were performed as previously described 
[51]. Briefly, cells were washed with cold PBS/1mM 
Na3VO4/10mM NaF. Protein isolation was performed 
using a scraper in the presence of cold M-PER lysis 
buffer (Thermo Scientific, Rockford, USA) containing 
1mM Na3VO4, 10mM NaF, anti-phosphatase and 
protease inhibitor. Protein was quantified using the 
BCA protein assay and was mixed with Laemmli 
Sample Buffer (Bio-Rad Laboratories, Mississauga, 
Ontario, Canada). After denaturing the lysate at 98°C 
for 6 min, 10 μg of each protein lysate was separated by 
1DSDS-PAGE (10%) and, transferred to nitrocellulose 
membranes. After blocking for 1 hr with 5%(w/v) non-
fat milk or BSA in TBST (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.1% Tween 20), membranes were incubated 
with primary antibodies overnight at 4°C followed by 
secondary antibodies (HRP-conjugated anti- mouse 
IgG) for 1hr at room temperature. Signals were detected 
with ChemiDoc Touch Imaging System (Bio-Rad 
Laboratories, Mississauga, Ontario, Canada) using 
prime ECL plus (Sigma). The primary and secondary 
antibodies are as follows: Anti-mouse IgG HRP-linked 
(sc-2005), GAPDH (sc-365062) and SYK (sc-1240) 
from Santa Cruz Biotechnology. For the tissue analysis 
of SYK, extracts were prepared from frozen sections 
of matched normal and tumor (ccRCC) by addition of 
Laemelli buffer to 10 um sections (total ~1 cm2 surface 
area). After protein quantitation by a modified Bradford 
assay, 5 μg protein were loaded per lane of a Criterion 
TGX 8-16% gradient gel (Biorad) and the blotting 
procedure carried out essentially as above but with a 
2 hour primary antibody incubation (1:20,000 dilution 
of anti-SYK). A Coomassie-stained parallel gel and 
densitometry was used to check equal loading together 
with Ponceau staining of the membrane to check for 
transfer.
Colony-formation assay
Cells transfected with siRNA constructs were 
trypsinized and plated in a 6-well plate as single cells 
(1000 cells/well). Every 4 days, the growth medium was 
removed, the cells were washed with fresh medium once, 
and then fresh medium was added to the wells. Colony 
formation assays were followed for 8 days, then the 
medium was removed and the cells were washed with 
PBS. Washed cells were fixed for 10 min by adding 3.7% 
Paraformaldehyde (Alfa Aesar, Great Britain), and 0.05% 
(v/v) crystal violet (Acros, New Jersey, USA) was added 
to cells for 10 min in order to obtain visible colonies. 
Images were acquired using scanner Epson perfection 
V800 (Epson, Jakarta, Indonesia).
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Quantitative real-time PCR
Total RNA was extracted from cells using miRNeasy 
kit (Qiagen) according to the supplier protocols. 1μg 
RNA was reverse transcribed into complementary DNA 
(cDNA) using Transcriptor First Strand cDNA Synthesis 
Kit (Roche, Germany) following instructions provided by 
the manufacturer. Real-time PCR reactions were prepared 
using Lightcycler 480 SYBR green I master kit (Roche), 
and were run on a LightCycler 480 instrument (Roche) 
according to the manufacturer’s recommendations. 
Triplicate PCR reactions were performed for each sample 
to ensure reliability. Expression of SYK-L mRNA was 
normalized to the expression of the housekeeping gene 
actin using the 2–[delta][delta]Ct method. The sequences 
of SYK and ACTIN primers were as follows:
ACTIN Forward, d (AGGCACCAGGGCGTGAT);
ACTIN Reverse, d (GCCCACATAGGAATCCTT 
CTGAC);
SYK-Long Forward, d (AGGGAAAGAAGTTCG 
ACACGCT);
SYK-Long Reverse, d (TTATTCCACCCGCTGAC 
CAAGT).
Availability
AbHAC is available as a user friendly publicly 
available R package in github under GPL-3 license 
(https://github.com/mehrankr/AbHAC). Scripts for 
reproducing tables and figures of this manuscript are also 
made available (https://bitbucket.org/mkarimzadeh/abhac_
suppcodes).
Cell viability and caspase 3/7 activity
CellTiter-Glo and Caspase-Glo 3/7 Assay kits 
(Promega, Madison, WI) were used to assess cell viability 
and apoptosis induction 48h (apoptosis) or 96h (cell viability) 
after siRNA transfection as previously described [52].
Cell cycle analysis
siRNA transfected cells were harvested after 48h by 
Accutase cell detachment solution (Sigma) and washed 
with cold PBS. Next we used cold Nicoletti buffer [53] 
for staining, and the DNA content of single nuclei was 
analyzed by BD FACSCanto II Flow Cytometry Analyzer 
Systems with collection of at least 10,000 events for each 
sample. The experiments were performed in triplicates.
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